110, 60216026. Nature 483, 484488. Special tests can show detailed information about the tumor cells. (WC/jensflorian), Minigemistocytes and mitoses. Oligodendroglioma resection: a Surveillance, Epidemiology, and End Results (SEER) analysis. ; Weaver, AL. Oligodendroglioma is a primary central nervous system (CNS) tumor. J. However, tumor samples collected from enhancing and non-enhancing areas for a scRNAseq analysis revealed an abundance of immune cells. Oligodendroglioma: Background, Pathophysiology, Epidemiology - Medscape However, a clear distinction of both grades is not always possible. Neuro Oncol. Neurosurgery 68, 13261333. "MAP-2e, a novel MAP-2 isoform, is expressed in gliomas and delineates tumor architecture and patterns of infiltration". This comes with a risk of sacrificing important brain centers and hence compromising functionality and quality of life. A neuropathologist should then review the tumor tissue. This previously diagnosed oligoastrocytoma,, For unequivocal assessment of 1p/19q codeletion in oligodendroglial tumors, detection of whole-arm losses, MeSH 53(2):140-8. Youmans and Winn Neurological Surgery. Oligodendroglioma - several images (upmc.edu), Oligodendroglioma with plasmacytoid cells (frontalcortex.com), http://www.emedicine.com/radio/topic481.htm, 10.1043/1543-2165(2007)131[242:CAOQLA]2.0.CO;2, https://librepathology.org/w/index.php?title=Oligodendroglioma&oldid=51960, Attribution-NonCommercial-ShareAlike 4.0 International, highly cellular lesion composed of cells resembling, intra-axial mass, +/-calcifications (best seen on CT), nonenhancing or enhancing. (2002). doi: 10.1212/wnl.51.4.1140, van den Bent, M., Taphoorn, M., Brandes, A., Menten, J., Stupp, R., Frenay, M., et al. While often found upregulated in many tumors, FUBP1 acts as a tumor suppressor gene due to its inactivating mutations reported in around 15% of oligodendroglial tumors (Baumgarten et al., 2014). Other treatments might be recommended if any tumor cells remain or if there's an increased risk that the tumor will come back. doi: 10.12786/bn.2022.15.e23. 0000144092 00000 n government site. 2008 Apr 15. 7(4):305-314. J. Clin. This review assesses the latest management modalities along with the pathways involved in the pathogenesis of this malignancies. CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas. J. Clin. PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. J. Mol. High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up.